Oruka Therapeutics reported earnings of -$ 0.63 per ORKA share on Nov 9, 2026, beating analysts' expectations by
| Report Date | Nov 9, 2026 |
|---|---|
| Forecasted EPS | -$ 0.60 |
| Earnings Per Share (Surprise) | -$ 0.63 (-$ 0.03) |
| Last Year's EPS | -$ 0.47 |
| EPS YoY Change |
Out of the last 40 earnings reporting periods, Oruka Therapeutics beat analysts’ expectations 11 times and fell short of expectations 3 time(s). Oruka Therapeutics reported earnings per share of -$ 0.63 in the last report falling to reach an estimated EPS of -$ 0.60 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 9, 2026 | -$ 0.60 | -$ 0.63 | -$ 0.55 | |
| Aug 10, 2026 | -$ 0.51 | -$ 0.55 | -$ 0.46 | |
| May 13, 2026 | -$ 0.55 | -$ 0.48 | -$ 0.40 | |
| Mar 12, 2026 | -$ 0.61 | -$ 0.45 | -$ 0.49 | |
| Nov 12, 2025 | -$ 0.56 | -$ 0.55 | -$ 1.46 | |
| Aug 11, 2025 | -$ 0.48 | -$ 0.46 | -$ 1.53 | |
| May 14, 2025 | -$ 0.57 | -$ 0.40 | -$ 0.76 | |
| Mar 6, 2025 | -$ 0.68 | -$ 0.49 | -$ 0.14 | |
| Nov 13, 2024 | -$ 0.40 | -$ 1.46 | -$ 0.08 | |
| Aug 27, 2024 | - | -$ 1.53 | -$ 0.10 | |
| Aug 1, 2024 | - | -$ 0.76 | -$ 0.10 | |
| Apr 25, 2024 | - | -$ 0.14 | -$ 0.09 | |
| Dec 31, 2023 | - | -$ 0.08 | -$ 0.98 | |
| Sep 30, 2023 | - | -$ 0.10 | -$ 1.94 | |
| Jun 30, 2023 | - | -$ 0.10 | -$ 2.62 | |
| Mar 31, 2023 | - | -$ 0.09 | -$ 2.72 | |
| Dec 31, 2022 | - | -$ 0.98 | -$ 4.73 | |
| Sep 30, 2022 | - | -$ 1.94 | -$ 3.92 | |
| Jun 30, 2022 | - | -$ 2.62 | -$ 4.03 | |
| Mar 31, 2022 | - | -$ 2.72 | -$ 3.98 |
Oruka Therapeutics’s stock was trading at $ 102.86 on Nov 8, 2026 a day before the last earnings report was released.Following the release of the earnings report, ORKA’s price increased to $ 109.50 on Nov 10, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 9, 2026 | -$ 0.63 | $ 102.86 | $ 109.50 | |
| Aug 10, 2026 | -$ 0.55 | $ 98.82 | $ 104.68 | |
| May 13, 2026 | -$ 0.48 | $ 64.65 | $ 63.90 | |
| Mar 12, 2026 | -$ 0.45 | $ 34.41 | $ 40.00 | |
| Nov 12, 2025 | -$ 0.55 | $ 28.20 | $ 26.38 | |
| Aug 11, 2025 | -$ 0.46 | $ 13.09 | $ 13.95 | |
| May 14, 2025 | -$ 0.40 | $ 9.62 | $ 9.46 | |
| Mar 6, 2025 | -$ 0.49 | $ 10.38 | $ 10.46 | |
| Nov 13, 2024 | -$ 1.46 | $ 26.10 | $ 24.00 | |
| Aug 27, 2024 | -$ 1.53 | $ 45.72 | $ 41.88 | |
| Aug 1, 2024 | -$ 0.76 | $ 36.00 | $ 37.32 | |
| Apr 25, 2024 | -$ 0.14 | $ 43.56 | $ 42.96 | |
| Dec 31, 2023 | -$ 0.08 | $ 20.40 | $ 20.16 | |
| Sep 30, 2023 | -$ 0.10 | $ 24.12 | $ 24.12 | |
| Jun 30, 2023 | -$ 0.10 | $ 24.24 | $ 24.48 | |
| Mar 31, 2023 | -$ 0.09 | $ 24.12 | $ 23.40 | |
| Dec 31, 2022 | -$ 0.98 | $ 28.44 | $ 29.04 | |
| Sep 30, 2022 | -$ 1.94 | $ 25.68 | $ 25.08 | |
| Jun 30, 2022 | -$ 2.62 | $ 30.00 | $ 29.76 | |
| Mar 31, 2022 | -$ 2.72 | $ 27.84 | $ 26.40 |
Oruka Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Oruka Therapeutics missed analysts’ expectations during the last earnings period by
